Table 1. Papillary thyroid cancer (PTC) patient specimen analysis (N=19)—characteristics and treatment table.
| De-ID | Histology | Age | BRAF status | TERT status | Meta-static disease | Lymph node involve ment | Stage at specimen collection | Staging edition | Specimen collection site | First-line treatment* | Additional lines of treatment* |
| 54 | Papillary thyroid carcinoma, macrofollicular variant | <55 | Negative | Negative | No | No | PT2N0M0, Stage I | V8 | Thyroid | Surgery (thyroidectomy) | N/A |
| 55 | Papillary thyroid carcinoma, classical | >55 | Positive | Positive | Yes | Yes | pT3bN1bM1, Stage IVC | V8 | Lymph Node | Palliative RT to spine mets; Surgery (thyroidectomy, nephrectomy) | N/A |
| 57 | Recurrent papillary thyroid carcinoma | <55, >45 | Positive | Negative | No | Yes | Recurrent pT4aN1bM0; Stage III | V7 | Larynx | Surgery (thyroidectomy, laryngectomy)+RAI | Sorafenib, lenvatinib, vemurafenib, compassionate use pembrolizumab, palliative RT+cyberknife, encorafenib+binimetinib |
| 58 | Mult micropapillary carcinomas, classical | <55 | Positive | Negative | No | Yes | pT1aN1aM0, Stage II | V8 | Thyroid | Surgery (thyroidectomy)+RAI | N/A |
| 59 | Papillary thyroid carcinoma | >55 | Positive | Negative | No | No | PT1bN0M0, Stage I | V8 | Thyroid | Surgery (thyroidectomy) | N/A |
| 60 | Metastatic papillary thyroid carcinoma, response to pembro | <55 | Positive | Negative | Yes | Yes | Recurrent pT1bN1aMx, Stage I | V8 | Thyroid | Surgery (thyroidectomy)+RAI | Surgical bed resection+RAI (recurrence), cediranib, lenvatinib, sorafenib, SRS x 5, compassionate use pembrolizumab, dabrafenib+trametinib, palliative RT |
| 61 | Papillary thyroid carcinoma, predominant follicular features | >55 | Negative | Negative | No | No | PT1bN0M0, Stage I | V8 | Thyroid | Surgery (hemithyroidectomy) | N/A |
| 63 | Metastatic papillary thyroid carcinoma; follicular adenoma, lymphocytic thyroiditis | <55 | Positive | Negative | No | Yes | pT3N1bM0; Stage I | V8 | Thyroid | Surgery (thyroidectomy)+RAI | N/A |
| 64 | Metastatic papillary thyroid carcinoma follicular variant; mild lymphocytic thyroiditis | <55 | Positive | Negative | No | No | pT1aN0M0, Stage I | V8 | Thyroid | Surgery (thyroidectomy and neck dissection)+RAI | N/A |
| 65 | Papillary thyroid carcinoma, classical, 6/39 LN positive for carcinoma | <55 | Positive | Negative | No | Yes | PT2N1aM0, Stage I | V8 | Thyroid | Surgery+RAI | N/A |
| 66 | Metastatic thyroid cancer, well-differentiated with follicular architecture. | <55 | Negative | Positive | Yes | Yes | pT3N0M1, Stage II | V8 | Brain | Surgery (thyroidectomy) in 2009; RAI in 2015 and 2016 | Resection+SRS of brain lesions |
| 67 | Anaplastic thyroid carcinoma, arising in association with PTC with focal tall cell features | >55 | Positive | Negative | Yes | Yes | pT2N1a,cM1, Stage IVC | V8 | Central Lymph Node | Surgery+Carbo/Taxol+Radiation | Lenvatinib |
| 69 | Metastatic papillary thyroid carcinoma, some tall cells | <55, >45 | Positive | Positive | Yes | Yes | pT1bN1bM1, Stage IVC | V7 | Neck Lymph Node | Surgery+RAI | Dabrafenib then lenvatinib |
| 70 | Locally recurrent multifocal PTC involving the paratracheal region & and central compartment, classical type | <55, <45 | Positive | Positive | No | Yes | T3N1bM0, Stage I | V7 | Neck Lymph Node | Surgery+RAI | ChemoXRT with cisplatin |
| 74 | Papillary (classical) thyroid carcinoma | >55 | Positive | Negative | No | PTC is NED | PT1N1bM0, Stage II | V8 | Central lymph node | Surgery | |
| 75 | Papillary thyroid carcinoma, focally invasive into perithyroid soft tissue; lymphocytic thyroiditis and adenomatous nodules; breast cancer | >55 | Negative | Positive | No | No | PT3N0M0, Stage II | V8 | Thyroid | Surgery | |
| 76 | Metastatic papillary thyroid carcinoma | <55, >45 | Positive | Positive | Yes | Yes | PT4aN1bM1, Stage IVc | V7 | Neck Mass | Surgery+RAI | Pembro then lenvatinib then dabrafenib/trametnib |
| 78 | Papillary thyroid carcinoma, conventional with focal squamous metaplasia | <55 | Positive | Positive | No | No | PT4aN0, Stage I | V8 | Thyroid | Surgery+RAI | |
| 79 | Papillary thyroid carcinoma, follicular variant | >55, >45 | Negative | Negative | Yes | Yes | PT4aN1bM0, Stage IVA | V7 | Neck Lymph Node | Surgery+RAI | Lenvatinib then entrectinib |
*
Patients were treated with current first-line SOC at the time of treatment or clinical trial. Subsequent treatments were chosen based on physician/patient preference.
N/Anot availableRAIradioactive iodine